{{01. pembrolizumab (Keytruda, Merck)
Kev muag khoom: $ 29.48 billion (+18%)
Cov ntsiab lus tseem ceeb: ib lub pd -1 inhibitor npog40+ txoj kev kho mob kheesxaws rau cov neeg ua haujlwm ua ntej ua ntej; tsim kho cov txheej txheem subcutaneous kom txuas ntxiv ntawm patent (qub patent tas sij hawm nyob rau hauv 2028) .
Cov kev sib tw: FDA npaj yuav txwv nws txoj kev siv hauv cov neeg mob uas muaj pd tsawg {{}} tawm.
{{02. semaglutide (Ozempic, Novo Nordisk)
Kev muag khoom: $ 16.9 billion (+26%)
Cov ntsiab lus tseem ceeb: lub GLP -1 Cov tshuaj siv rau hom kab mob ntshav qab zib hom 2, kev tiv thaiv kev tiv thaiv kev tiv thaiv kab mob plawv, thiab mob raum mob ntsws; tseem ceeb yav tom ntej kev loj hlob muaj peev xwm {{2} Cov kev cov nyom uas txo qis (I {}} new n {} {.
3. Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy, Gilead)
Kev muag khoom: $ 13.4 billion (+13%)
Cov ntsiab lus tseem ceeb: Kev siv tshuaj HIV ntau tshaj 50% ntawm U . s} Kev ua lag luam, nrog tsis muaj kev cuam tshuam txog li ntawm IT ...}}
{{0 {}} aphasaban (elixaban (elixas, BMS / Pfizer)
Kev muag khoom: $ 13.3 billion (+9%)
Cov ntsiab lus tseem ceeb: cov ntshav tshuab los ntshav nrog kev ua haujlwm vam meej ua lag luam .
Cov kev cov nyom: patent tas sij hawm nyob rau hauv 2026, nrog cov generics twb tau pom zoo; ib tug 56% tus nqi txiav tom qab IRA kev sib tham, ua rau cov tuam txhab xaiv cov nqi {}}
Cov kev cov nyom: patent tas sij hawm nyob rau hauv 2026, nrog cov generics twb tau pom zoo; ib tug 56% tus nqi txiav tom qab IRA kev sib tham, ua rau cov tuam txhab xaiv cov nqi {}}
5. dupilumab (dupixent, Sanofi / Regeneron)
Kev muag khoom: $ 13 billion (+23%)
Cov ntsiab lus tseem ceeb: Tshuaj tiv thaiv kev txhaj tshuaj rau atopic dermatitis, mob hawb pob, thiab cov kab mob pulmonitive tshiab (cops), nrog patent tiv thaiv kom txog thaum 2031.
{{0 {}} pisankizumab (skyrizi, abbvie)
Kev muag khoom: $ 13 billion (+23%)
Cov ntsiab lus tseem ceeb: Tshuaj tiv thaiv kev txhaj tshuaj rau atopic dermatitis, mob hawb pob, thiab cov kab mob pulmonitive tshiab (cops), nrog patent tiv thaiv kom txog thaum 2031.
{{0 {}} pisankizumab (skyrizi, abbvie)
Kev muag khoom: $ 11.7 BILLION (+50.9%)
Cov ntsiab lus tseem ceeb: ant -23 cov tshuaj nrog kev tiv thaiv kev nrawm, muaj kev tiv thaiv patent ntawm 2031.
{{07. daratumabab (Darzalex, Johnson & Johnson)
Kev muag khoom: $ 11.7 BILLION (+20%)
Cov ntsiab lus tseem ceeb: Ntau Myeloma Tshuaj nrog tshuaj Patent nrog kev tiv thaiv patent ntawm 2029, tsav tsheb hauv J & J's Oncology Portfolio {}}
8.} Ustekinumab (Stelara, Johnson & Johnson)
Kev muag khoom: $ 10. 5.3 billion (-4.6%)
Cov ntaub ntawv tseem ceeb: kev tawm tsam uas nws muag tsis kam lees vim Biosimar kev sib tw tom qab cov khoom tiav patent tom 2023.
{{0 {}} adAlimumab (humira, Abbvie)
Kev muag khoom: $ 9 billion (-37.6%)
Cov ntsiab lus tseem ceeb: Thaum lub ntiaj teb muag tshuaj zoo tshaj plaws tom qab muaj kev tso cai rau BiCotment tom qab 82% (Q}) txog 72% (2024).
{{0 {}} gardasil (merck)
Kev muag khoom: $ 8.6 billion (-3%)
Cov ntsiab lus tseem ceeb: PLAUB XWB cov tshuaj tiv thaiv cov npe, pom zoo rau cov txiv neej nyob rau hauv Suav teb xyoo 2024, tab sis cov khoom xa tawm vim yog cov lus nug siab; patent tas sij hawm tas sij hawm nyob rau hauv 2028, nrog kev tsis paub cai ua ntej {2.
Ntsiab lus qhia
Kev loj hlob tsav tsheb: oncology immunothere), tus kab mob metabolic (Ozempic kab mob (skyunotherapies (DupXent) yog cov chaw loj hlob loj .
TSEEM NYEM: PATORA / EXTREN LWM TUS NQI LOS (IRA Kev cuam tshuam nrog Ozempic / Eliempility (Humira / Stelara).
Cov Tswv Yim Ua Lag Luam: Tsim cov qauv tshiab ntawm cov ntawv sau (Darzalex / Ozempic Tswj (txuas kev tiv thaiv) {}}}
